Trial status April 2020

In Africa

The aim of the EBL2002 study in Africa is to test the vaccine for safety and immunogenicity in a total of 1,056 study participants including healthy adults and population groups including the elderly, HIV-infected adults, adolescents and children. In total, 1,885 participants have been screened and 1,075 have been randomized across cohort 1 (669 healthy adults), cohort 2A (142 HIV-infected individuals), cohort 2B (132 healthy adolescents aged 12 to 17 years) and cohort 3 (132 children aged 4 to 11 years) of which 1,017 have received the Dose 2 vaccination. 

A booster dose (Ad26.ZEBOV) was given to 90 study participants to confirm the establishment of memory and development of an anamnestic response. 

All study cohorts are now completed. Sample analyses are still ongoing on cohort 2B (132 healthy adolescents aged 12 to 17 years) and cohort 3 (132 children aged 4 to 11 years).

In Europe

The EBL2001 trial in Europe (UK, France) has been completed. 423 study participants have been randomized (143 were randomized in reporting year 1 and 280 in reporting year 2), of which 290 have received the second dose vaccination. The site close-out visits have been performed. Volunteers are now being followed for five years in a long-term safety follow-up study, EBL4001.

Sample core analysis has been completed in the US for the main immune response. The focus is now on the additional immunogenicity testing conducted in France and in the UK.

From a scientific perspective

Thanks to the finalisation of Cohort 1, the first results in EBOVAC2 on the immune response to the vaccine were obtained by the Oxford Vaccine Group (UOXF) in a subcohort of 30 participants in the UK.  During the last 12 months, UOXF has been characterising the B cell response to Ad26.ZEBOV/MVA.BN.Filo and has shown strong plasma cell responses and also identified their phenotypes. The group has also begun preliminary analysis of the antibody VH-gene response post Ad prime and MVA boost and initial isolation of monoclonal antibodies has been achieved by the Townsend group.

News

  • Ebovac2 at ECCMID 2019 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 7th EBOVAC2 Newsletter 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • EBOVAC1/2 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • EBOVAC1 consortium reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination - 14th March 2017 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • EBOVAC2 report on BBC News - 8th March 2017 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

  • The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016. 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research